Defence Therapeutics Stock Analysis
| DTCFF Stock | USD 0.47 0.02 4.44% |
Defence Therapeutics' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Defence Therapeutics' financial risk is the risk to Defence Therapeutics stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Defence Therapeutics' debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Defence Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Defence Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Defence Therapeutics is said to be less leveraged. If creditors hold a majority of Defence Therapeutics' assets, the OTC Stock is said to be highly leveraged.
Defence Therapeutics is overvalued with Real Value of 0.42 and Hype Value of 0.47. The main objective of Defence Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Defence Therapeutics is worth, separate from its market price. There are two main types of Defence Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Defence Therapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Defence Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Defence |
Defence OTC Stock Analysis Notes
The company recorded a loss per share of 0.15. Defence Therapeutics had not issued any dividends in recent years. Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.The quote for Defence Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Defence Therapeutics call Sebastien Plouffe at 514 947 2272 or check out https://defencetherapeutics.com.Defence Therapeutics Investment Alerts
| Defence Therapeutics generated a negative expected return over the last 90 days | |
| Defence Therapeutics has high historical volatility and very poor performance | |
| Defence Therapeutics has some characteristics of a very speculative penny stock | |
| Defence Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Defence Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Defence Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Defence Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Defence to invest in growth at high rates of return. When we think about Defence Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (7.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Defence Therapeutics has accumulated about 506.7 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Cabaletta Bio to Participate in Guggenheim Emerging Outlook Biotech Summit 2026 - Quiver Quantitative |
Defence Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 143.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Defence Therapeutics's market, we take the total number of its shares issued and multiply it by Defence Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 15th of February 2026, Defence Therapeutics shows the Variance of 26.9, mean deviation of 3.95, and Standard Deviation of 5.19. Defence Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Defence Therapeutics, which can be compared to its peers. Please confirm Defence Therapeutics variance, as well as the relationship between the maximum drawdown and skewness to decide if Defence Therapeutics is priced favorably, providing market reflects its regular price of 0.47 per share. As Defence Therapeutics is a penny stock we also recommend to verify its jensen alpha numbers.Defence Therapeutics Price Movement Analysis
Study |
The minimum time period for execution of this function requires larger time horizon. Please increase the time horizon for this function. The output start index for this execution was zero with a total number of output elements of zero. The Instantaneous Trendline is a moving-average-like indicator which is formed by removing the Dominant Cycle from Defence Therapeutics price series.
Defence Therapeutics Predictive Daily Indicators
Defence Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Defence Therapeutics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Defence Therapeutics Forecast Models
Defence Therapeutics' time-series forecasting models are one of many Defence Therapeutics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Defence Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Defence Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Defence Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Defence Therapeutics, which in turn will lower the firm's financial flexibility.About Defence OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Defence Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Defence shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Defence Therapeutics. By using and applying Defence OTC Stock analysis, traders can create a robust methodology for identifying Defence entry and exit points for their positions.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biologicalbiosimilar therapeutic drugs for cancer and infectious diseases. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada. Defence Therapeutics is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Defence Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Complementary Tools for Defence OTC Stock analysis
When running Defence Therapeutics' price analysis, check to measure Defence Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Defence Therapeutics is operating at the current time. Most of Defence Therapeutics' value examination focuses on studying past and present price action to predict the probability of Defence Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Defence Therapeutics' price. Additionally, you may evaluate how the addition of Defence Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |